UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

Journal of clinical oncology, 2002-07, Vol.20 (13), p.2943-2950

2002

Volltextzugriff (PDF)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

British journal of cancer, 2001-01, Vol.84 (1), p.42-47

2001

Volltextzugriff (PDF)

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

HemaSphere, 2022-06, Vol.6 (Suppl), p.1893-1894

2022

Volltextzugriff (PDF)

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2005, Vol.55 (1), p.91-99

2005

Volltextzugriff (PDF)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐4 STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.830-831

2022

Volltextzugriff (PDF)

Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers

Journal of pharmaceutical sciences, 1997-07, Vol.86 (7), p.808-812

1997

Volltextzugriff (PDF)

1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Anti-cancer drugs, 1999-09, Vol.10 (8), p.719-728

1999

Volltextzugriff (PDF)

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE‐AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM‐14

HemaSphere, 2022-06, Vol.6, p.1893-1894

2022

Volltextzugriff (PDF)

Glutathione catalysis of interconversion of acitretin and its 13-cis isomer isoacitretin

Journal of pharmaceutical sciences, 1990-05, Vol.79 (5), p.444-446

1990

Volltextzugriff (PDF)

Dose proportionality of transdermal nitroglycerin

Pharmaceutical research, 1992-10, Vol.9 (10), p.1284-1289

1992

Volltextzugriff (PDF)

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

Journal of clinical pharmacology, 2014-07, Vol.54 (7), p.818-827

2014

Volltextzugriff (PDF)

Effects of Probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans

Clinical pharmacology and therapeutics, 1994-08, Vol.56 (2), p.133-141

1994

Volltextzugriff (PDF)

Food Increases the Bioavailability of Acitretin

Journal of clinical pharmacology, 1988-11, Vol.28 (11), p.1051-1055

1988

Volltextzugriff (PDF)

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

British journal of haematology, 2015-07, Vol.170 (1), p.40-49

2015

Volltextzugriff (PDF)

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects

Pharmacology research & perspectives, 2018-07, Vol.6 (4), p.e00408-n/a

2018

Volltextzugriff (PDF)

Phase I study to characterize pharmacokinetics (PK) of topotecan (T) at 4 mg/m 2 administered weekly as a 30-minute IV infusion

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.13551-13551

2008

Volltextzugriff (PDF)

Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2003-2003

2004

Volltextzugriff (PDF)

Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2003-2003

2004

Volltextzugriff (PDF)

The interaction of alpha-1-acid glycoprotein with endogenous autocoids, in particular, platelet activating factor (PAF)

Progress in clinical and biological research, 1989, Vol.300, p.307

1989

Volltextzugriff (PDF)

Behaviour of platinum/platinum-rhodium thermocouples at high temperatures

Journal of scientific instruments, 1951-11, Vol.28 (11), p.353-353

1951

Volltextzugriff (PDF)

Down's syndrome, hypothyroidism and diabetes mellitus in an adult

Medical journal of Australia, 1979-07, Vol.2 (1), p.9-10

1979

Volltextzugriff (PDF)

Studies on the thermal destruction of Escherichia coli endotoxin

Journal of parenteral science and technology : a publication of the Parenteral Drug Association, 1987-03, Vol.41 (2), p.49

1987

Volltextzugriff (PDF)

α 1-Acid glycoprotein high-performance liquid chromatography column (EnantioPAC) as a screening tool for protein binding

Journal of chromatography, 1989-02, Vol.487 (2), p.257-264

1989

Volltextzugriff (PDF)

1 – 25 von 807

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(690)
Mit Volltextzugriff
(651)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(512)
Life Sciences & Biomedicine
(367)
Humans
(336)
Female
(225)
Biological And Medical Sciences
(181)
Male
(174)
Medical Sciences
(157)
Adult
(140)
Middle Aged
(140)
Aged
(103)
Physical Sciences
(102)
Animals
(76)
Technology
(67)
Adolescent
(54)
Oncology
(54)
Aged, 80 And Over
(51)
Exact Sciences And Technology
(48)
Astronomy & Astrophysics
(45)
Surgery
(44)
Gastroenterology. Liver. Pancreas. Abdomen
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐4 STUDY

Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers

1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE‐AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM‐14

Glutathione catalysis of interconversion of acitretin and its 13-cis isomer isoacitretin

Dose proportionality of transdermal nitroglycerin

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

Effects of Probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans

Food Increases the Bioavailability of Acitretin

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects

Phase I study to characterize pharmacokinetics (PK) of topotecan (T) at 4 mg/m 2 administered weekly as a 30-minute IV infusion

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab

Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar

Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar

The interaction of alpha-1-acid glycoprotein with endogenous autocoids, in particular, platelet activating factor (PAF)

Behaviour of platinum/platinum-rhodium thermocouples at high temperatures

Down's syndrome, hypothyroidism and diabetes mellitus in an adult

Studies on the thermal destruction of Escherichia coli endotoxin

α 1-Acid glycoprotein high-performance liquid chromatography column (EnantioPAC) as a screening tool for protein binding

Suchergebnisse filtern